TrianglePaclitaxel (NCT06245889)
Paclitaxel trial for Triple Negative Breast Cancer (NCT06245889). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with stage II–III triple-negative breast cancer; estrogen and progesterone receptor staining up to 10% is allowed.
The idea: four cycles of paclitaxel and carboplatin accompany pembrolizumab, which releases an immune brake. MRI response guides whether additional chemotherapy with pembrolizumab is recommended before surgery. Patients may instead choose surgery. PET scans and blood tests explore early response markers; later treatment depends on surgical findings.
This phase 2 study plans 30 patients. Cesar Santa-Maria leads at Johns Hopkins; the record lists two recruiting entries in Baltimore.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.